Curis (NASDAQ:CRIS – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Curis to post earnings of ($1.36) per share and revenue of $2.04 million for the quarter.
Curis Price Performance
Curis stock opened at $3.01 on Wednesday. Curis has a 1-year low of $2.86 and a 1-year high of $17.49. The company has a market cap of $25.49 million, a PE ratio of -0.39 and a beta of 3.41. The stock’s 50 day moving average price is $3.30 and its 200 day moving average price is $4.28.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Curis in a research note on Tuesday, December 10th.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
See Also
- Five stocks we like better than Curis
- How to Buy Cheap Stocks Step by Step
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What Makes a Stock a Good Dividend Stock?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to start investing in penny stocks
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
